Clinical Trials
37
Trial Phases
5 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (36 trials with phase data)• Click on a phase to view related trials
Safety, Tolerability, and Pharmacokinetic Profile of Grammidin With Anesthetic, a Metered Dose Topical Spray in Healthy Volunteers
- Conditions
- Pharyngitis
- Interventions
- Drug: Grammidin with anesthetic neoDrug: Grammidin with anesthetic, a metered dose topical spray
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 24
- Registration Number
- NCT06857890
- Locations
- 🇷🇺
Separate Medical Unit "CoMed" (LLC "Ligand Research"), Moscow, Russian Federation
Safety, Tolerability, and Pharmacokinetic Profile of Grammidin, a Metered Dose Topical Spray in Healthy Volunteers
- Conditions
- Pharyngitis
- Interventions
- Drug: Grammidin neoDrug: Grammidin, a metered dose topical spray
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-07-10
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 24
- Registration Number
- NCT06859281
- Locations
- 🇷🇺
Limited Liability Company "Research Center Eco-Safety", Saint Petersburg, Russian Federation
Study of the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of Ingavirin Forte, Capsules, Folliwing Single and Subsequent Multiple Oral Administration in Healthy Volunteers
- Conditions
- InfluenzaViral Respiratory Infection
- Interventions
- Drug: Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 5 mgDrug: Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 10 mgDrug: Combined preparation of imidazolylethylamide of pentanedioic acid and N,N'-bis-[2-(1,3-diazocyclopenta-2,4-dien-4-yl)ethyl] diamide of malonic acid, 90 mg + 20 mg
- First Posted Date
- 2025-03-05
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 36
- Registration Number
- NCT06859333
- Locations
- 🇷🇺
State Budgetary Healthcare Institution of the City of Moscow "City Clinical Hospital No. 15 named after O.M. Filatov of the Department of Health of Moscow.", Moscow, Russian Federation
Efficacy and Safety of Ranquilon in Patients With Anxiety Disorders Due to Neurasthenia and Adjustment Disorders
- Conditions
- AnxietyNeurastheniaAdjustment Disorders
- Interventions
- Drug: Afobazole
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 250
- Registration Number
- NCT06843044
- Locations
- 🇷🇺
Engels Psychiatric Hospital State Health Care Institution of the Ministry of Health of the Saratov Region, Engels, Russian Federation
🇷🇺Unimed-C Jsc, Moscow, Russian Federation
🇷🇺Aurora MedFort LLC, Saint Petersburg, Russian Federation
Efficacy, Safety, and Tolerability of 4-MUST Tablets in Chronic Cholecystitis and Biliary Dyskinesia
- Conditions
- Chronic CholecystitisBiliary Dyskinesia
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-07-11
- Lead Sponsor
- Valenta Pharm JSC
- Target Recruit Count
- 300
- Registration Number
- NCT06842966
- Locations
- 🇷🇺
State autonomous health care institution "Engels City Clinical Hospital No. 1", Engels, Russian Federation
🇷🇺Ivanovo Kuvaev Clinical Hospital, Ivanovo, Russian Federation
🇷🇺State Budgetary Institution of Healthcare of Moscow "City Polyclinic No. 2 of the Moscow Department of Healthcare", Moscow, Russian Federation
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next